eligibility_summary
Eligibility Summary: Patients: Multiple myeloma diagnosed after 1/1/2017, KPS >70%, ≥2 prior lines, expected to start a new RRMM therapy within 12 months, age 18–80, English or Spanish, willing to consent and complete procedures. Exclusions: active CNS disease or a definitive treatment plan. Investigators: must be a co-investigator and agree to comply with study procedures.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06126341 (PROACT PCD) is an observational study in relapsed/refractory multiple myeloma assessing barriers to using cellular therapies. No therapeutic drugs are given. Interventions are behavioral assessments (HADS, Duke-UNC Functional Social Support, Distress Thermometer, FACT-BMT, PACT) and a physician education lecture. Therapies under evaluation (not administered): 1) BCMA-directed CAR T cells—type: autologous, gene‑modified cellular therapy, mechanism: engineered CAR on T cells recognizes BCMA (TNFRSF17) on malignant plasma cells, activating T-cell cytotoxicity and cytokine release to kill myeloma cells. 2) Hematopoietic cell transplantation (HCT)—procedure, mechanism: high-dose therapy followed by stem cell rescue to reconstitute hematopoiesis and enable disease control. Targets: malignant plasma cells (BCMA), T lymphocytes as effectors (CAR T), and hematopoietic stem/progenitor cells (HCT), pathways include BCMA signaling and T-cell cytotoxic/immune synapse activation.